Free  Victims of health products: a European opportunity to be seized

Marketing Authorisations

Insulin icodec (Awiqli°) in type 1 or type 2 diabetes

Bedaquiline (Sirturo°) in first-line treatment for pulmonary multidrug-resistant tuberculosis

Bedaquiline (Sirturo°) in pulmonary multidrug-resistant tuberculosis from 5 years of age

Teduglutide (Revestive°) in short bowel syndrome from 4 months of age

Modified attenuated dengue tetravalent vaccine (Qdenga°)

Bupropion + naltrexone (Mysimba°) in excess body weight: still marketed, to the detriment of patients

Editors' opinion. Amnesia?

Lebrikizumab (Ebglyss°) in atopic eczema

Abrocitinib (Cibinqo°) in atopic eczema from 12 years of age

Efgartigimod alfa (Vyvgart°) by subcutaneous injection

Adverse Effects

Drug-induced sleep apnoea

Gliflozins: increased risk of amputations and peripheral revascularisation procedures (continued)

Caftors: liver function abnormalities and possibly cataracts in breastfed infants

Common stem: -ciclib

Denosumab: severe, even fatal, hypocalcaemia

Severe liver injury: dozens of drugs implicated, many victims

Benfluorex: still cases of pulmonary hypertension, 15 years after its market withdrawal

BRAF inhibitors: uveitis

Outlook

Depakine°: mother who sounded the alarm finally receives compensation

Exposure to titanium dioxide via drugs

Free  European drug regulatory agencies: strategy through to 2028

Free  EMA: handling the competing interests of its experts

Masthead

Free  Masthead